GlassScriptPhysician profile
Jeffrey B Petersen
NPI 1699794735
$1,368.96
in general payments reported to CMS, 2019-2025
25 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $106 · 2022: $89.05 · 2023: $271 · 2024: $196 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $714.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $290.08 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $260.02 | 2019-2025 | Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $88.25 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Pfizer INC. | $87.18 | 2019-2024 | |
| Allergan, INC. | $82.16 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $65.60 | 2022-2024 | Austedo Xr |
| Abbott Laboratories | $47.41 | 2019-2023 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.02 | 2019 | |
| Abbvie INC. | $36.08 | 2023 | |
| Lilly USA, LLC | $34.87 | 2020-2023 | Mounjaro, Trulicity |
| Amgen INC. | $33.30 | 2019-2023 | Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $31.69 | 2025 | |
| Cranial Technologies, INC | $28.88 | 2019-2022 | |
| Astellas Pharma US INC | $28.22 | 2019 | |
| Mannkind Corporation | $25.65 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $24.31 | 2019 | |
| Novo Nordisk INC | $23.20 | 2019 | |
| Ibsa Pharma INC. | $22.54 | 2025 | Flector, Licart, Tirosint |
| Exact Sciences Corporation | $21.62 | 2025 | Cologuard Collection Kit |
| Phadia US INC. | $19.70 | 2023 | Immunocap |
| Collegium Pharmaceutical, INC. | $18.61 | 2025 | Belbuca |
| Becton, Dickinson and Company | $18.30 | 2024 | Bd Onclarity |
| Galderma Laboratories, L.P. | $15.89 | 2024 | |
| Genentech USA, INC. | $12.96 | 2019 | |
| Scilex Pharmaceuticals INC. | $12.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Petersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.